Samuelson Doug
Known title: Chief Financial OfficerCIK: 0001943326
Samuelson Doug's purchase track record
Samuelson Doug has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2024 | KAPA | $4K | -20.6% | -64.4% | -2.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| KAPA | ▲ Buy | Grant | 152,672 | $0 | 10/8/2025 | View on chart |
| KAPA | ▲ Buy | Open Market | 2,500 | $4K | 11/22/2024 | View on chart |
| GNLX | ▼ Sell | Open Market | 1,297 | $31K | 8/18/2023 | View on chart |
| GNLX | ▲ Buy | Grant | 3,600 | $0 | 2/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Kairos Pharma Reports Positive Phase 2 Data for ENV-105
Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.
Kairos Pharma Reports Positive Phase 2 Data for ENV-105. Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.